Argatroban Abstracts, News, & Events

Keep up-to-date on the latest Abstracts, News, and Events related to HIT and Argatroban. Be sure to check back often as we continue to add information in the coming months.

Disclaimer

The www.argatroban.com Web site contains links to third-party Web sites on the Internet. These links are provided as a service to individuals interested in more information in HIT. These sites are not part of this GlaxoSmithKline (GSK) Web site. The content and materials in these third-party Web sites are not produced or endorsed by GSK and may refer to uses of our products that are not recommended by GSK.

2006 Abstracts

View Archive

Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Soc Crit Care Med, Feb 2006.

Jang IK, Baron SJ, Hursting MJ, Anglade E. Heparin-induced thrombocytopenia and argatroban therapy in women.
14th Annual Congress on Women's Health, June 2006.

Gray T, Wallis DE, Katz E, Hursting MJ, Lewis BE. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
Amer Coll Clin Pharmacy, Oct 2006.

Levine RL, Hergenroeder GW, Francis JL. Prevalence of heparin-platelet factor 4 antibodies in surgical and medical intensive care units.
Amer Coll Chest Physicians, Oct 2006.

Czyz Y, Hoffman WD, Gay SR, Hursting MJ. Argatroban therapy for heparin-induced thrombocytopenia after coronary artery bypass graft surgery.
Am Soc Health-System Pharmacists, Dec 2006.

Rice L, Hursting MJ, McCollum DA. Argatroban anticoagulation for heparin-induced thrombocytopenia in obese, versus non-obese, patients.
Blood 2006;108 (11 part 1 of 2):431a. (Presented at Amer Soc Hematology, Dec 2006).

Alexy T, Tucker S, Boyle S, Rochanda L, Hood D, Rowe VL, Weaver FA, Liebman HA. Heparin-PF4 antibodies are frequent after vascular surgery, but not a frequent cause of graft thrombosis or thrombocytopenia.
Blood 2006;108 (11 part 1 of 2):430a. (Presented at Amer Soc Hematology, Dec 2006).

Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Blood 2006;108 (11 part 2 of 2):106b.

Guzzi L, Hursting MJ, McCollum D. Argatroban treatment for heparin-induced thrombocytopenia with renal impairment.
Soc Crit Care Med, Feb 2007.

News

Coming Soon

Events

Coming Soon

Indications
Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.

Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).

Important Safety Information

As with all anticoagulants, bleeding is a serious concern. Argatroban is contraindicated in patients with overt major bleeding or those with hypersensitivity to the product or any of its components. Argatroban should be used with extreme caution in disease states or other circumstances in which there is an increased risk of hemorrhage. Overall major bleeding was reported in 5.3% of patients with HIT treated with Argatroban versus 6.7% of the historical controls. Overall major bleeding was reported in 1.8% of patients undergoing PCI treated with Argatroban versus 3.1% of the historical controls. Intracranial bleeding was not observed in the 568 patients treated with Argatroban for HIT (with or without thrombosis) or in the 91 patients who underwent PCI. The most common nonhemorrhagic side effects in HIT patients, regardless of the relationship to treatment, were dyspnea, hypotension, and fever. In patients undergoing PCI, the nonhemorrhagic side effects, regardless of the relationship to treatment, included chest pain, hypotension, and back pain. Please see full Prescribing Information for additional safety information on Argatroban.